EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up

Xi Qin, Yulan Liu, Lin Zhu, Yunyan Mo, Jing Zhang, Zhuchun Jiang, Dongning Huang, Xinrong Hu, Jingzhang Li, Quanfang Chen, Feng Xue

Oncology Research · 2025

DOI: 10.32604/or.2025.064119 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology Research, 2025. Verfasst von Xi Qin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China. Hauptthemen laut MEDLINE: Acrylamides, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases.

Methods

The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events (AEs) were assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0).

Results

Approximately 47 patients with EGFR-Mutant aNSCLC were recruited, including 1 squamous cell carcinoma (SCC) patient, 1 EGFR G719C mutated patient, 1 EGFR S768 patient mutated, and 1 EGFR KDD mutated patient. The average follow-up duration was 48.1 months concluding in August 2024. The median PFS (mPFS) was 22.2 months (95% CI 17.6 to 26.7), while the median OS (mOS) was 39.7 months (95% CI 32.6 to 46.9). Patients with deletion of exon19 in EGFR (19del) showeda mPFS of 28.4 months, markedlylonger than those with the L858R point mutation (L858R), who had a mPFS of 15.2 months (p = 0.036). Overall, 22 patients (46.8%) had central nervous system (CNS) metastases at the basal level. The mPFS for this cohort was 19.7 months. Rashes (17.0%), skin decrustation (4.2%), pruritus (4.2%), dental ulcers (4.2%), increased creatine kinase (2.1%), and musculoskeletal pains (2.1%) were the most prevalent AEs in this study. Grade 3 and higher AEs were observed at a rate of 4.2%.

Conclusion

This study concluded that aumolertinib has considerable safety and efficacy for EGFR-mutant NSCLC in a first-line defense.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedErbB ReceptorsFollow-Up StudiesRetrospective StudiesAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

Aumolertinibepidermal growth factor receptor (EGFR)non-small cell lung cancer (NSCLC)real worldsafety

Substanzen

AcrylamidesEGFR protein, humanErbB ReceptorsosimertinibProtein Kinase InhibitorsAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
  • Department of Radiotherapy, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
  • Department of Oncology, Guilin People's Hospital, Guilin, 541300, China.
  • Department of Oncology and Integrated Traditional Chinese and Western Medicine, The People's Hospital of Hezhou, Hezhou, 542899, China.
  • Department of Oncology, Liuzhou Workers' Hospital, Liuzhou, 545001, China.
  • Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541002, China.

Zitieren

APA

Qin, X., Liu, Y., Zhu, L., Mo, Y., Zhang, J., Jiang, Z., Huang, D., Hu, X., Li, J., Chen, Q., & Xue, F. (2025). First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up. Oncology Research. https://doi.org/10.32604/or.2025.064119

Vancouver

Qin X, Liu Y, Zhu L, Mo Y, Zhang J, Jiang Z, et al. First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up. Oncology Research. 2025. doi:10.32604/or.2025.064119

BibTeX
@article{Qin2025,
  author = {Qin, Xi and Liu, Yulan and Zhu, Lin and Mo, Yunyan and Zhang, Jing and Jiang, Zhuchun and Huang, Dongning and Hu, Xinrong and Li, Jingzhang and Chen, Quanfang and Xue, Feng},
  title = {First-Line Aumolertinib in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up},
  journal = {Oncology Research},
  year = {2025},
  doi = {10.32604/or.2025.064119}
}
Kostenlos starten →